Skip to main content
Caplight Logo









Invectys

Invectys

Private
Houston, TexasHealthcare & Life Scienceshttps://invectys.com

Last Round

Early Funding

Oct 10, 2024

Total Funding Raised

$40.1M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Invectys is a biopharmaceutical company that develops innovative immunotherapy approaches to treat cancer by targeting HLA-G and telomerase antigens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyCAR-T cell therapysolid tumor treatmentHLA-Gmonoclonal antibodynanobodyDNA vaccinecancer vaccineoncologybiopharmaceuticalimmune checkpointcell therapyclinical-stage biotechtumor antigendrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invectys Comparables

Compare Invectys with similar companies based on industry and business-model similarity.

Invectys comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AffyImmune Therapeutics
83%
NKILT Therapeutics
80%
Tizona Therapeutics
79%

Invectys Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 10, 2024
GrantMay 20, 2020
Series AOct 29, 2018
Early FundingJul 1, 2017

Key People

Founding team and executive leadership

Jake A Kushner

Chief Executive Officer

Executive Team

Virginie Leplat

COO

Executive Team

Invectys Investors

Notable investors and investment history

Invectys investors
InvestorRounds
Cancer Prevention and Research Institute of TexasGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Monthly visitors increased 202% MoM, reaching 1.1K.

  • Mar 1, 2026

    Monthly visitors increased 68% MoM.

Invectys Filings

Explore SEC and related filing metadata, where available.

Invectys filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Invectys's valuation, stock price, and market status.

Is Invectys a public or private company?

Invectys is a private company.

What is the current stock price of Invectys?

Invectys is a private company with no public stock price. No recent secondary market data is available.

How much is Invectys worth (valuation)?

Valuation information for Invectys is not publicly available.

Can I buy Invectys stock?

Invectys shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Invectys's last funding round?

Invectys's most recent funding round was Early Funding on October 10, 2024.

Who are the main investors in Invectys?

Key investors in Invectys include Cancer Prevention and Research Institute of Texas.

Will Invectys IPO soon?

No public IPO plans have been announced for Invectys.

How can I track Invectys secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Invectys's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Employee Range11
Year Founded2010
Last FundingOct 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?